"Hepatitis C, Chronic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
| Descriptor ID |
D019698
|
| MeSH Number(s) |
C02.440.440.120 C02.782.350.350.120 C06.552.380.350.120 C06.552.380.705.440.120
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hepatitis C, Chronic".
Below are MeSH descriptors whose meaning is more specific than "Hepatitis C, Chronic".
This graph shows the total number of publications written about "Hepatitis C, Chronic" by people in this website by year, and whether "Hepatitis C, Chronic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 3 | 0 | 3 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hepatitis C, Chronic" by people in Profiles.
-
Freidel MR, Armen RS. Modeling the Structure-Activity Relationship of Arbidol Derivatives and Other SARS-CoV-2 Fusion Inhibitors Targeting the S2 Segment of the Spike Protein. J Chem Inf Model. 2021 12 27; 61(12):5906-5922.
-
Hawkins C, Grant J, Ammerman LR, Palella F, Mclaughlin M, Green R, Mcgregor D, Stosor V. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective. J Antimicrob Chemother. 2016 09; 71(9):2642-5.
-
Tholey DM, Ahn J. Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma. Gastroenterol Clin North Am. 2015 Dec; 44(4):761-73.
-
Pothineni NV, Rochlani Y, Vallurupalli S, Kovelamudi S, Ahmed Z, Hakeem A, Mehta JL. Comparison of Angiographic Burden of Coronary Artery Disease in Patients With Versus Without Hepatitis C Infection. Am J Cardiol. 2015 Oct 01; 116(7):1041-4.
-
Pasquinelli C, McPhee F, Eley T, Villegas C, Sandy K, Sheridan P, Persson A, Huang SP, Hernandez D, Sheaffer AK, Scola P, Marbury T, Lawitz E, Goldwater R, Rodriguez-Torres M, Demicco M, Wright D, Charlton M, Kraft WK, Lopez-Talavera JC, Grasela DM. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother. 2012 Apr; 56(4):1838-44.
-
Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, Herrine SK, Harrison SA, Poordad FF, Koury K, Deng W, Noviello S, Pedicone LD, Brass CA, Albrecht JK, McHutchison JG. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology. 2010 Nov; 139(5):1602-11, 1611.e1.
-
Santos C, Herrine SK. Making the best of a bad situation: early chronic nosocomial HCV infection. Dig Dis Sci. 2010 Jun; 55(6):1509-11.
-
Hashemi N, Rossi S, Navarro VJ, Herrine SK. Safety of peginterferon in the treatment of chronic hepatitis C. Expert Opin Drug Saf. 2008 Nov; 7(6):771-81.
-
Mitchell DG, Navarro VJ, Herrine SK, Bergin D, Parker L, Frangos A, McCue P, Rubin R. Compensated hepatitis C: unenhanced MR imaging correlated with pathologic grading and staging. Abdom Imaging. 2008 Jan-Feb; 33(1):58-64.
-
Guttman OT, Soffer RJ, Rosenblatt MA. The ultrasound-guided supraclavicular-interscalene (UGSCIS) block: a case report. Pain Pract. 2008 Jan-Feb; 8(1):62-4.